Allianz Asset Management’s Vaxcyte PCVX Stock Holding History

Allianz Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Buy	7,891 +791	+11%	+$43K	﹤0.01%	2002
2026 Q1	$413K	Hold	7,100	–	–	﹤0.01%	1863
2025 Q4	$328K	Buy	+7,100	New	+$318K	﹤0.01%	1885
2025 Q2	–	Sell	-6,800	Closed	-$257K	–	2226
2025 Q1	$257K	Hold	6,800	–	–	﹤0.01%	2077
2024 Q4	$557K	Sell	6,800 -700	-9%	-$69.5K	﹤0.01%	1828
2024 Q3	$857K	Hold	7,500	–	–	﹤0.01%	1684
2024 Q2	$566K	Hold	7,500	–	–	﹤0.01%	1790
2024 Q1	$512K	Sell	7,500 -2,500	-25%	-$173K	﹤0.01%	1616
2023 Q4	$628K	Buy	10,000 +1,500	+18%	+$77.9K	﹤0.01%	1777
2023 Q3	$433K	Buy	+8,500	New	+$419K	﹤0.01%	1977

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Allianz Asset Management's PCVX Position: Q2 2026 in Review

Allianz Asset Management increased its Vaxcyte (PCVX) stake by 11% in Q2 2026, buying an estimated $43K and bringing the position to 7,891 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

Allianz Asset Management first reported a position in PCVX in Q3 2023 and has held it in 10 quarters since. The position peaked at $857K in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Allianz Asset Management held 7,891 shares of Vaxcyte worth $459K as of Q2 2026.
Allianz Asset Management bought 791 Vaxcyte shares in Q2 2026, an estimated $43K.
Vaxcyte made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2002 holding.
Allianz Asset Management first reported a position in Vaxcyte in Q3 2023 and has held it in 10 quarters since.
Allianz Asset Management's Vaxcyte position peaked at $857K in Q3 2024.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.